Introduction
============

Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating event accounted for 5% of all stroke cases ([@B24]; [@B10]). The incidence of aSAH is approximately 9 per 100,000, and the mortality is approximately 60% within 6 months ([@B26]). The surgical treatment of aSAH includes endovascular coiling and surgical clipping. However, there are a lot of complications frequently occur after successful surgery ([@B4]; [@B26]), such as cerebral vasospasm, rebleeding, or hydrocephalus. Cerebral vasospasm typically appears on the third day after aSAH, is maximal at 6--8 days, and subsequently lasts 2--3 weeks ([@B36]). There are approximately 23% of deaths or disabilities in patients with aSAH due to cerebral vasospasm ([@B12]). Delayed cerebral vasospasm is considered as the major cause of poor outcomes in aSAH patients in subsequent decades ([@B7]).

According to the past research, cerebral vasospasm after aSAH was regarded as an outcome of many factors, such as inflammatory changes, abnormal endothelial hypertrophy, prolonged contraction of the smooth muscle cells, and gene expression in the brain arteries ([@B21]). In addition, it seems possible that disruptions in either or both nitric oxide and endothelin-1 metabolism may play key roles in the pathogenesis of cerebral vasospasm ([@B8]). Consequently, various methods are used to prevent cerebral vasospasm on the basis of its pathogenesis, such as the endothelin antagonist clazosentan, the cholesterol-lowering agent simvastatin, and the vasodilator magnesium sulfate, calcium channel blocker nicardipine ([@B31]; [@B37]; [@B30]). However, some researchers find that the prevention of cerebral vasospasm does not improve the outcomes of aSAH patients ([@B18]; [@B32]; [@B17]).

Acupuncture has been used to treat aSAH effectively and safely for centuries ([@B11]). In recent years, numerous studies have demonstrated that acupuncture can increase the content of nitric oxide in vascular endothelial cell, activate the activity, and improve the function of injured vascular endothelial cells ([@B2]; [@B13]). In addition, acupuncture or EA at the Baihui (GV20) and left Zusanli (ST36) acupoints in rat model significantly reduces the expression of the proinflammatory enzyme MMP2 and the water channel proteins AQP4, to relieve inflammation related brain edema ([@B38]). Therefore, we hypothesized that EA might be used to improve cerebral vasospasm and the outcomes of patients with aSAH. In this study, we recruited 60 age- and sex-matched volunteers and performed a case--control study to investigate and validate the impact of EA treatment on patients with aSAH from a Chinese Han population.

Materials and Methods {#s1}
=====================

Participants
------------

This double-blinded, randomized controlled study was approved by the Ethics Committee of Ningbo First Hospital. A total of 60 age- and sex-matched aSAH patients from Department of Neurosurgery, who were randomly allocated by computer algorithm to the study group (*n* = 30) or the control group (*n* = 30). Inclusion criteria were as follows: (1) the individuals were aged older than 18 years and had the ability to begin acupuncture treatment within 24 h after aSAH; (2) aSAH were independently diagnosed by at least two neurosurgeons using computed tomography and cerebral angiography; (3) the patients with aneurysm who had been treated by the operative treatment such as endovascular coiling or surgical clipping; (4) written informed consent was obtained before the study. Exclusion criteria were as follows: (1) the patients with traumatic or infectious aSAH; (2) the patients without ability to undergo TCD; (3) the patients with severe heart, hepatic and renal dysfunctions; (4) the patients with cardiac pacemaker; or (5) the patients with a previous EA experience.

Intervention
------------

EA treatment started within 24 h of aSAH, after intracranial aneurysm surgery including endovascular coiling or surgical clipping. EA was applied four times in 2 weeks, and it was performed by the same acupuncturist with over 10 years acupuncture treatment experience. At the same time, standard medicine treatments, such as hemodilution (triple-H) therapy, nimodipine, hypertension control, and hypervolemic, were appropriated for all patients.

Study and Control Group
-----------------------

The patients in the study group were administered EA therapy using HANS100A analgesic apparatus (Nanjing Jisheng Medical Technology Co., Nanjing, China) with a dilatational wave of 2 Hz in the GV20 position. The electric current was gradually increased (0 up to 5 mA), and the speed depended on the patient's pain threshold. Each treatment session based on the electric current intensity of 5 mA and lasted 30 min. EA treatment was performed on the 1st, 3rd, 5th, and 7th days after the operation. The MFV in the MCA was measured by TCD (Prosound α10, Aloka Co, Ltd, Tokyo, Japan) before and after EA therapy (**Figure [1](#F1){ref-type="fig"}**). The MFV was calculated according to the primary study ([@B16]). The control group received standard medicine treatments as same as the study group, but without EA treatment. In addition, cerebral vasospasm was measured by CTP on the 1st, 7th, and 14th day after surgery, and the dates of CBF, CBV, and MTT were collected.

![The MFV in the MCA was measured by TCD. PSV, peak systolic velocity; EDV, end-diastolic velocity; MFV, mean flow velocity; MCA, middle cerebral artery; TCD, transcranial doppler; EA, electroacupuncture. A 52-year-old female patient with subarachnoid hemorrhage caused by rupture of right anterior communicating artery aneurysm, developed vasospasm on the 5th day after surgery. The maximum value of flow velocity in systole was calculated at the apex of the waveform, which defined as PSV. EDV was measured at end diastole, and indicated the lowest point of waveform. MFV was calculated as EDV plus a third of the difference between PSV and EDV (MFV \[cm/s\] = \[PSV + 2EDV\]/3). TCD detection showed that the MFV in MCA in the range of 120∼140 cm/s was indicative of mild cerebral vasospasm, 140∼200cm/s was accord with moderate cerebral vasospasm, and above 200 cm/s was consistent with severe cerebral vasospasm. **(A)** TCD showed a high MFV in MCA (144.1cm/s) before EA. **(B)** The MFV in MCA (90.3cm/s) was decreased after EA.](fnins-12-00724-g001){#F1}

Statistics
----------

The sample size was calculated based on the primary study. The incidence rate of delayed ischemic neurological deficit in the acupuncture group was 10%, and the control group was 38.9% ([@B3]). To detect a significance level of 0.05 between the groups with 80% power at the assumption of a drop-out rate of 20% and a 1-tailed α = 0.05, 54 patients (27 participants in each group) were required for this study ([@B25]). Data were represented as mean ± standard deviation (SD) or number (%) and analyzed using SPSS version 23.0 (IBM Corp. Armonk, NY, United States) software. Categorical variables were analyzed with the chi-square test or Fisher's exact test, and the means of continuous variables were analyzed using the Student's *t*-test. Statistical significance was defined as a *p*-value of \<0.05.

Results
=======

Clinical Characteristics of the Subjects
----------------------------------------

The clinical characteristics of the patients are presented in **Table [1](#T1){ref-type="table"}**. The control group consisted of 30 aSAH patients (13 males and 17 females) with a mean age of 51.9 ± 9.51 years. The study group underwent EA therapy and consisted of 30 aSAH patients (13 males and 17 females) with a mean age of 52.67 ± 11.27 years. No significant differences in the aneurysm location (*p* = 0.612), aneurysms therapies (*p* = 0.121), Hunt-Hess grade (*p* = 0.793), and Fisher grade (*p* = 0.279) were noted between the two groups.

###### 

Patient characteristics of the two groups.

  Characteristics                        Study group (*n* = 30)   Control group (*n* = 30)   *p*-value
  -------------------------------------- ------------------------ -------------------------- -----------
  Age(years)                             52.67 ± 11.27            51.9 ± 9.51                0.777
  Male/female                            13/17                    13/17                      1.000
  Aneurysm location                                                                          0.612
  Anterior communicating Artery          13                       13                         
  Posterior communicating Artery         7                        10                         
  Middle cerebral artery                 2                        3                          
  Posterior inferior cerebellar artery   3                        0                          
  Basilar artery                         0                        1                          
  Vertebral artery                       2                        1                          
  Supraclinoid internal carotid artery   2                        1                          
  Multiple intracranial aneurysms        1                        1                          
  Aneurysms therapies                                                                        0.121
  Coiling                                4                        26                         
  Clipping                               0                        30                         
  Hunt--Hess grade                                                                           0.793
  I--II                                  17                       18                         
  III--V                                 13                       12                         
  Fisher grade                                                                               0.279
  I                                      7                        12                         
  II-III                                 19                       13                         
  IV                                     4                        5                          
                                                                                             

Age was analyzed using student's

t

-test and other data were analyzed using chi-square test.

Cerebral Vasospasm Was Measured by CTP
--------------------------------------

Significant differences in CBF, CBV, and MTT variations were noted in both groups on the 1st, 7th, and 14th days after surgery (all *p* \< 0.001, **Table [2](#T2){ref-type="table"}**, **Figures [2A--C](#F2){ref-type="fig"}**). The CBF was considerably increased in the study group on the 14th day after surgery (study group vs. control group: 47.10 ± 7.79 vs. 41.52 ± 5.65, *p* = 0.002, **Table [3](#T3){ref-type="table"}**, **Figure [2D](#F2){ref-type="fig"}**). The CBV was markedly increased in the study group compared with the control group on the 1st (study group vs. control group: 3.84 ± 0.68 vs. 4.20 ± 0.53, *p* = 0.026), 7th (study group vs. control group: 3.57 ± 0.67 vs. 3.19 ± 0.54, *p* = 0.020), and 14th days (study group vs. control group: 4.33 ± 0.66 vs. 3.79 ± 0.59, *p* = 0.001, **Table [3](#T3){ref-type="table"}**, **Figure [2E](#F2){ref-type="fig"}**) after surgery. Besides, the MTT was considerably reduced in the study group compared with the control group on the 1st (study group vs. control group: 6.89 ± 0.92 vs. 7.82 ± 1.16, *p* = 0.001), 7th (study group vs. control group: 7.43 ± 0.98 vs. 8.48 ± 1.15, *p* \< 0.001), and 14th (study group vs. control group: 6.81 ± 0.97 vs. 9.50 ± 1.17, *p* \< 0.001, **Table [3](#T3){ref-type="table"}**, **Figure [2F](#F2){ref-type="fig"}**) days after surgery.

###### 

The changes in CBF, CBV, and MTT in the two groups over time.

                  Variable             1^st^ day      7th day        14th day       *p*-value
  --------------- -------------------- -------------- -------------- -------------- -----------
                  CBF (mL/100 g/min)   37.40 ± 7.44   33.26 ± 6.20   47.10 ± 7.79   \<0.001
  Study group     CBV (mL/100 g)       3.84 ± 0.68    3.57 ± 0.67    4.33 ± 0.66    \<0.001
                  MTT (s)              6.89 ± 0.92    7.43 ± 0.98    6.81 ± 0.97    \<0.001
                  CBF (mL/100 g/min)   38.05 ± 6.94   33.15 ± 6.76   41.52 ± 5.65   \<0.001
  Control group   CBV (mL/100 g)       4.20 ± 0.53    3.19 ± 0.54    3.79 ± 0.59    \<0.001
                  MTT (s)              7.82 ± 1.16    8.48 ± 1.15    9.50 ± 1.17    \<0.001
                                                                                    

CBF, cerebral blood flow; CBV, cerebral blood volume; MTT, mean transit time.

All the data were analyzed using student's

t

-test.

![The CBF, CBV, MTT in two groups. CBF, cerebral blood flow; CBV, cerebral blood volume; MTT, mean transit time. All the data were analyzed using student's *t*-test. **(A)** CBF variations in the two groups based on time after surgery. **(B)** The variation in CBV in the two groups based on time after surgery. **(C)** The variation in the MTT of the two groups based on time after surgery. **(D)** The difference in CBF in two groups on the 1^st^, 7^th^, and 14^th^ day after surgery. **(E)** The difference in CBV in the two groups on the 1^st^, 7^th^, and 14^th^ day after surgery. **(F)** The difference in MTT in the two groups on the 1^st^, 7^th^, and 14^th^ day after surgery.](fnins-12-00724-g002){#F2}

###### 

Comparisons of CBF, CBV, and MTT in the two groups over time.

  Variable                   Study group    Control group   *p*-value
  -------------------------- -------------- --------------- -----------
  CBF1^st^ (mL/100 g/min)    37.40 ± 7.44   38.05 ± 6.94    0.727
  CBF7^th^ (mL/100 g/min)    33.26 ± 6.20   33.15 ± 6.76    0.944
  CBF14^th^ (mL/100 g/min)   47.10 ± 7.79   41.52 ± 5.65    0.002
  CBV1^st^ (mL/100 g)        3.84 ± 0.68    4.20 ± 0.53     0.026
  CBV7^th^ (mL/100 g)        3.57 ± 0.67    3.19 ± 0.54     0.020
  CBV14^th^ (mL/100 g)       4.33 ± 0.66    3.79 ± 0.59     0.001
  MTT1^st^ (s)               6.89 ± 0.92    7.82 ± 1.16     0.001
  MTT7^th^ (s)               7.43 ± 0.98    8.48 ± 1.15     \<0.001
  MTT14^th^ (s)              6.81 ± 0.97    9.50 ± 1.17     \<0.001
                                                            

CBF1st/7th/14th, cerebral blood flow on the 1

st

, 7

th

, and 14

th

day after surgery, respectively; CBV1st/7th/14

th

, cerebral blood volume on the 1

st

, 7

th

, and 14

th

day after surgery, respectively; MTT1st/7

th

/14

th

, mean transit time on the 1

st

, 7

th

, and 14

th

day after surgery, respectively. All the data were analyzed using student's

t

-test.

Cerebral Vasospasm Was Relieved After EA Therapy and Measured by TCD
--------------------------------------------------------------------

As presented in **Table [4](#T4){ref-type="table"}**, statistically significant variations in the MFV levels of MCA were noted between the two groups based on the length of time after surgery. Significant differences in the MFV of MCA were noted between the two groups on the 3rd (study group vs. control group: 115.32 ± 19.22 vs. 124.60 ± 15.80, *p* = 0.046), 5th (study group vs. control group: 117.34 ± 18.49 vs. 128.68 ± 14.37, *p* = 0.010), and 7th (study group vs. control group: 108.19 ± 16.16 vs. 124.94 ± 14.85, *p* \< 0.001, **Table [4](#T4){ref-type="table"}**, **Figure [3A](#F3){ref-type="fig"}**) day after surgery. In the study group, all patients accepted EA therapy at the same time point after surgery (1st, 3rd, 5th, and 7th day), and the MFV in MCA was significantly reduced compared with that measured post-EA on the 1st (Pre-EA vs. Post-EA: 118.49 ± 20.38 vs. 109.12 ± 18.40, *p* \< 0.001), 3rd (Pre-EA vs. Post-EA: 125.29 ± 22.51 vs. 115.32 ± 19.22, *p* \< 0.001), 5th (Pre-EA vs. Post-EA: 128.37 ± 22.15 vs. 117.34 ± 18.49, *p* \< 0.001), and 7th (Pre-EA vs. Post-EA: 118.94 ± 18.61 vs. 108.19 ± 16.16, *p* \< 0.001, **Table [5](#T5){ref-type="table"}**, **Figure [3B](#F3){ref-type="fig"}**) day.

###### 

The MFV level in MCA in the two groups.

  Time day       Study group      Control group    *p*-value
  -------------- ---------------- ---------------- -----------
  1^st^ (cm/s)   109.12 ± 18.40   117.42 ± 17.67   0.080
  3^rd^ (cm/s)   115.32 ± 19.22   124.60 ± 15.80   0.046
  5^th^ (cm/s)   117.34 ± 18.49   128.68 ± 14.37   0.010
  7^th^ (cm/s)   108.19 ± 16.16   124.94 ± 14.85   \<0.001
  *p-*value      \<0.001          \<0.001          
                                                   

MFV, mean flow velocity; MCA, middle cerebral artery. All the data were analyzed using student's

t

-test.

![The MFV in MCA and the outcome in the two groups. MFV, mean flow velocity; MCA, middle cerebral artery. The GOS score was used 1 or 3 months after surgery to assess the clinical outcome of patient survival. **(A)** Comparison of MFV in MCA in the study group versus control group on the 1^st^, 3^rd^, 5^th^, and 7^th^ day after surgery. The data were analyzed using student's *t*-test. **(B)** Comparison of MFV in MCA in the study group pre-EA versus post-EA on the 1^st^, 3^rd^, 5^th^, and 7^th^ day after surgery. The data were analyzed using student's *t*-test. **(C)** Comparison of outcome in the study group versus control group 1 month after surgery The data were analyzed using chi-square test. **(D)** Comparison of outcome in the study group versus control group 3 months after surgery. The data were analyzed using chi-square test.](fnins-12-00724-g003){#F3}

###### 

The MFV level in MCA in the study group.

                    MFV1^st^         MFV3^rd^         MFV5^th^         MFV7^th^
  ----------------- ---------------- ---------------- ---------------- ----------------
  Pre-EA (cm/s)     118.49 ± 20.38   125.29 ± 22.51   128.37 ± 22.15   118.94 ± 18.61
  Post- EA (cm/s)   109.12 ± 18.40   115.32 ± 19.22   117.34 ± 18.49   108.19 ± 16.16
  *p*-value         \<0.001          \<0.001          \<0.001          \<0.001
                                                                       

EA, electroacupuncture; MFV, mean flow velocity; MCA, middle cerebral artery; MFV1

st

/3

rd

/5

th

/7

th

, mean flow velocity in the study group on the 1

st

, 3

rd

, 5

th

, and 7

th

day after the operation.

All the data were analyzed using student's t-test.

Patients With aSAH Exhibited a Better Outcome After EA Treatment
----------------------------------------------------------------

The GOS score was used 1 or 3 months after surgery to assess the clinical outcome of patient survival. Significant differences were noted in the outcomes of the two groups at 1 (*p* \< 0.001, **Table [6](#T6){ref-type="table"}**, **Figure [3C](#F3){ref-type="fig"}**) and 3 months (*p* = 0.001, **Table [6](#T6){ref-type="table"}**, **Figure [3D](#F3){ref-type="fig"}**) after surgery, and more patients exhibited a good outcome in the study group.

###### 

The outcome of aSAH patients in the two groups.

                  1 Month after aSAH   3 Months after aSAH                        
  --------------- -------------------- --------------------- ---- -- ---- ------- ----
  Study group     24                                         6       29           1
  Control group   7                                          23      19           11
  *p*-value                            \<0.001                            0.001   
                                                                                  

aSAH, Aneurysmal subarachnoid hemorrhage; GOS, Glasgow Outcome Scale. All the data were analyzed using chi-square test.

Discussion
==========

Cerebral ischemia after aSAH is a complex complication involving delayed cerebral vasospasm that may cause clinical deterioration, cerebral infarctionand death. Cerebral vasospasm after aSAH may related with multifactorial etiology, and this hypothesis was confirmed by the massive available treatment modalities. Currently, strong evidence supports that nimodipine and the triple-H therapy are benefits for cerebral vasospasm patients ([@B1]). Many treatments have improved the prognosis, but the neurological outcomes remain poor in the patients with delayed cerebral vasospasm. Therefore, it is urgent to identify safer and more efficacious methods to manage cerebral vasospasm and improve the outcomes of aSAH patients. EA is a advanced therapy on the basis of combination of traditional acupuncture and modern electrotherapy and is recommended as a treatment for stroke ([@B15]). Here, our results demonstrate that EA at GV20 significantly reduces cerebral vasospasm after aSAH and improves the outcomes of aSAH patients.

Acupuncture at the Baihui (GV20) acupoint had been used to treat stroke for hundreds of years ([@B34]). Currently, scientists revealed that acupuncture Baihui (GV20) could protect the neuro in ischemic stroke animal models. [@B6] study suggested that EA preconditioning of the Baihui (GV20) acupoint could ease the brain edema and attenuate blood--brain barrier disruption via effecting the related protein activity. [@B14] found that EA at the Baihui (GV20) and Dazhui (GV14) acupoints could increase CBF and improve the functional recovery in acute moderate focal cerebral ischemia. [@B33] reported that EA pretreatment at the Baihui (GV20) acupoint could protect the brain against transient ischemic injury through activating the anti-inflammatory proteins. Given that cerebral vasospasm begins 24--72 h after aSAH, early intervention of EA is urgent and necessary. In our study, in all patients who accepted EA therapy after coiling or clipping, the occurrence of rebleeding during EA treatment was avoided. In addition, to ensure the safety of all patients, treatment with nimodipine and other supporting agents was also administered. There are various advantages of EA compared with manual acupuncture. EA can be performed standardly, measured objectively, and controlled fully. Besides, EA has also been recommended for clinical trials and mechanistic research on acupuncture ([@B28]).

In our study, cerebral vasospasm was monitored by CTP and TCD. CTP has been used in patients with aSAH ([@B27]; [@B29]) and has rapidly gained popularity given its simplicity, speed, and veracity ([@B35]). CTP can detect the reduction of CBF, prolongation of MTT, and the status of CBV ([@B5]). Moreover, threshold values of 35 mL/100 g/min for CBF and 5.5 s for MTT are suggested for the diagnosis of cerebral vasospasm ([@B22]), and CBV exhibited the lowest diagnostic accuracy among all variables ([@B19]). The results of this study demonstrated that the CBV and MTT were significantly different between the study and control groups at 1, 7, and 14 days after surgery, whereas CBF exhibited statistical significance only 14 days after surgery. In addition, TCD works on that blood-flow velocity within an artery increases as the artery narrows, result in doppler frequency shift ([@B20]). The maximum value of flow velocity in systole was calculated at the apex of the waveform, which defined as PSV ([@B9]). EDV was measured at end diastole, and indicated the lowest point of waveform ([@B9]). MFV was calculated as EDV plus a third of the difference between PSV and EDV (MFV \[cm/s\] = \[PSV + 2EDV\]/3) ([@B16]). TCD detection showed that the MFV in MCA in the range of 120 ∼ 140 cm/s was indicative of mild cerebral vasospasm, 140 ∼ 200 cm/s was accord with moderate cerebral vasospasm, and above 200 cm/s was consistent with severe cerebral vasospasm ([@B23]). A skilled researcher operated TCD monitoring at a specific time every other day. In our study, the MFV levels of MCA were significantly reduced after EA treatment in the same patients. Additionally, the MFV levels of MCA in patients with EA treatment were markedly reduced than the control group. These findings suggest that EA is a potential method to relieve cerebral vasospasm after aSAH. Recent study suggested that EA Baihui (GV20) and Dazhui (GV14) could significantly increase cerebral cortex acetylcholine release, and repair nerve damage ([@B14]). Several studies have demonstrated that acupuncture enhances the nitric oxide production and increases local circulation ([@B28]). [@B6] found that EA at GV20 could reduce MMP2 and the water channel proteins, AQP4 and AQP9, which repair brain injury and improve functional outcomes depending on the mitigation of inflammation-related brain edema in model rats. We believe that these effects may explain the main mechanism through which EA treatment improves patient outcomes, and the outcome of the study group was significantly improved than the control group. Therefore, we think that the effect of EA treatment appears after it is continuously applied to aSAH patients over a 2-week period.

Study Limitations
-----------------

Apparently, our research has several limitations. First, only one center was included in this study, multicenter with a more homogeneous samples were needed to certificate the specific treatment effect in the future. Second, only a limited number of measurement timepoints were included in the study, so more frequent timepoints in the assessment of cerebral vasospasm should be included in future studies. Third, protein signaling pathways were not investigated in the current study, but should be a focus of future research. Fourth, the craniotomy procedure might affect cerebral vasospasm and the curative effect of EA therapy. Thus, a comparison between the clipping and coiling group is required in the future.

Conclusion
==========

In summary, our study confirmed that cerebral vasospasm was presented in patients with aSAH. EA therapy at the Baihui (GV20) position could increase the MFV of cerebral circulation and improve the outcome of aSAH patients. It is a safe and convenient treatment to improve cerebral vasospasm and the outcomes of aSAH patients.
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